Faculty Opinions recommendation of Cost-effectiveness of phosphate binders among patients with chronic kidney disease not yet on dialysis: a long way to go.

Author(s):  
Luis Ruilope ◽  
Enrique Morales
2019 ◽  
pp. 2-3

Impaired phosphate excretion by the kidney leads to Hyperphosphatemia. It is an independent predictor of cardiovascular disease and mortality in patients with advanced chronic kidney disease (stage 4 and 5) particularly in case of dialysis. Phosphate retention develops early in chronic kidney disease (CKD) due to the reduction in the filtered phosphate load. Overt hyperphosphatemia develops when the estimated glomerular filtration rate (eGFR) falls below 25 to 40 mL/min/1.73 m2. Hyperphosphatemia is typically managed with oral phosphate binders in conjunction with dietary phosphate restriction. These drugs aim to decrease serum phosphate by binding ingested phosphorus in the gastrointestinal tract and its transformation to non-absorbable complexes [1].


Author(s):  
Hamid Ravaghi ◽  
Mahdi Ebrahimnia ◽  
Ali Farzaneh ◽  
Zohreh Rostami ◽  
Mohammad Hasan Hashemi Madani

2013 ◽  
Vol 80 (07) ◽  
pp. 17-22 ◽  
Author(s):  
Sagrario Soriano ◽  
Raquel Ojeda ◽  
Mencarnación Rodríguez ◽  
Yolanda Almadén ◽  
Mariano Rodríguez ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document